MSI-H Cancer
8
4
6
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
A Beta-only IL-2 ImmunoTherapY Study
Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies